IPP Bureau
University of Glasgow opens Mazumdar Shaw Advance Research Centre
By IPP Bureau - June 10, 2022
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
National Ayurveda Research Institute for Panchakarma bags NABL Accreditation
By IPP Bureau - June 09, 2022
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
By IPP Bureau - June 09, 2022
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Krsnaa Diagnostics bags contract in Tripura
By IPP Bureau - June 08, 2022
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
Merck and Ridgeback announce new data for investigational molnupiravir
By IPP Bureau - June 08, 2022
Based on a post hoc analysis, fewer required respiratory interventions
Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients
By IPP Bureau - June 08, 2022
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Eugia Pharma receives USFDA Approval for Leuprolide Acetate Injection
By IPP Bureau - June 08, 2022
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
By IPP Bureau - June 08, 2022
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod
By IPP Bureau - June 08, 2022
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Tetra Bio-Pharma opens new subsidiary in Australia
By IPP Bureau - June 08, 2022
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Halozyme announces commercial launch of testosterone undecanoate 'TLANDO'
By IPP Bureau - June 08, 2022
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Prolacta Bioscience appoints David Steinberg as CFO
By IPP Bureau - June 08, 2022
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
India is dedicated to ensure health Security for every citizen: Mandaviya
By IPP Bureau - June 08, 2022
States have an important role in ensuring food safety and healthy food practices.
Cabinet approves MoU signed between India and USA in health sector
By IPP Bureau - June 08, 2022
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
NHA organizes orientation workshop on Ayushman Bharat Digital Mission in Mumbai
By IPP Bureau - June 08, 2022
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
